Sintilimab (10) and Camrelizumab (11) and TA regimen (atilizumab combined with bevacizumab) (12) are used as first-line drugs for the treatment of hepatocellular carcinoma, and they are humanized anti-programmed death receptor 1 (PD-1) monoclonal antibodies. Here, RPL17 is linked to hepatocellular carcinoma.